File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3389/fcvm.2021.713191
- PMID: 34660715
- WOS: WOS:000708911300001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Circulating Biomarkers for Cardiovascular Disease Risk Prediction in Patients With Cardiovascular Disease
Title | Circulating Biomarkers for Cardiovascular Disease Risk Prediction in Patients With Cardiovascular Disease |
---|---|
Authors | |
Keywords | adipocyte B-type natriuretic peptide cardiac troponin coronary artery disease fibroblast growth factor |
Issue Date | 2021 |
Publisher | Frontiers Research Foundation. The Journal's web site is located at https://www.frontiersin.org/journals/cardiovascular-medicine |
Citation | Frontiers in Cardiovascular Medicine, 2021, v. 8, p. article no. 713191 How to Cite? |
Abstract | Cardiovascular disease (CVD) is the leading cause of death globally. Risk assessment is crucial for identifying at-risk individuals who require immediate attention as well as to guide the intensity of medical therapy to reduce subsequent risk of CVD. In the past decade, many risk prediction models have been proposed to estimate the risk of developing CVD. However, in patients with a history of CVD, the current models that based on traditional risk factors provide limited power in predicting recurrent cardiovascular events. Several biomarkers from different pathophysiological pathways have been identified to predict cardiovascular events, and the incorporation of biomarkers into risk assessment may contribute to enhance risk stratification in secondary prevention. This review focuses on biomarkers related to cardiovascular and metabolic diseases, including B-type natriuretic peptide, high-sensitivity cardiac troponin I, adiponectin, adipocyte fatty acid-binding protein, heart-type fatty acid-binding protein, lipocalin-2, fibroblast growth factor 19 and 21, retinol-binding protein 4, plasminogen activator inhibitor-1, 25-hydroxyvitamin D, and proprotein convertase subtilisin/kexin type 9, and discusses the potential utility of these biomarkers in cardiovascular risk prediction among patients with CVD. Many of these biomarkers have shown promise in improving risk prediction of CVD. Further research is needed to assess the validity of biomarker and whether the strategy for incorporating biomarker into clinical practice may help to optimize decision-making and therapeutic management. |
Persistent Identifier | http://hdl.handle.net/10722/307884 |
ISSN | 2023 Impact Factor: 2.8 2023 SCImago Journal Rankings: 0.863 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wong, YK | - |
dc.contributor.author | Tse, HF | - |
dc.date.accessioned | 2021-11-12T13:39:18Z | - |
dc.date.available | 2021-11-12T13:39:18Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Frontiers in Cardiovascular Medicine, 2021, v. 8, p. article no. 713191 | - |
dc.identifier.issn | 2297-055X | - |
dc.identifier.uri | http://hdl.handle.net/10722/307884 | - |
dc.description.abstract | Cardiovascular disease (CVD) is the leading cause of death globally. Risk assessment is crucial for identifying at-risk individuals who require immediate attention as well as to guide the intensity of medical therapy to reduce subsequent risk of CVD. In the past decade, many risk prediction models have been proposed to estimate the risk of developing CVD. However, in patients with a history of CVD, the current models that based on traditional risk factors provide limited power in predicting recurrent cardiovascular events. Several biomarkers from different pathophysiological pathways have been identified to predict cardiovascular events, and the incorporation of biomarkers into risk assessment may contribute to enhance risk stratification in secondary prevention. This review focuses on biomarkers related to cardiovascular and metabolic diseases, including B-type natriuretic peptide, high-sensitivity cardiac troponin I, adiponectin, adipocyte fatty acid-binding protein, heart-type fatty acid-binding protein, lipocalin-2, fibroblast growth factor 19 and 21, retinol-binding protein 4, plasminogen activator inhibitor-1, 25-hydroxyvitamin D, and proprotein convertase subtilisin/kexin type 9, and discusses the potential utility of these biomarkers in cardiovascular risk prediction among patients with CVD. Many of these biomarkers have shown promise in improving risk prediction of CVD. Further research is needed to assess the validity of biomarker and whether the strategy for incorporating biomarker into clinical practice may help to optimize decision-making and therapeutic management. | - |
dc.language | eng | - |
dc.publisher | Frontiers Research Foundation. The Journal's web site is located at https://www.frontiersin.org/journals/cardiovascular-medicine | - |
dc.relation.ispartof | Frontiers in Cardiovascular Medicine | - |
dc.rights | This Document is Protected by copyright and was first published by Frontiers. All rights reserved. It is reproduced with permission. | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | adipocyte | - |
dc.subject | B-type natriuretic peptide | - |
dc.subject | cardiac troponin | - |
dc.subject | coronary artery disease | - |
dc.subject | fibroblast growth factor | - |
dc.title | Circulating Biomarkers for Cardiovascular Disease Risk Prediction in Patients With Cardiovascular Disease | - |
dc.type | Article | - |
dc.identifier.email | Wong, YK: debbieyk@hku.hk | - |
dc.identifier.email | Tse, HF: hftse@hkucc.hku.hk | - |
dc.identifier.authority | Tse, HF=rp00428 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3389/fcvm.2021.713191 | - |
dc.identifier.pmid | 34660715 | - |
dc.identifier.pmcid | PMC8517145 | - |
dc.identifier.hkuros | 329502 | - |
dc.identifier.hkuros | 329272 | - |
dc.identifier.volume | 8 | - |
dc.identifier.spage | article no. 713191 | - |
dc.identifier.epage | article no. 713191 | - |
dc.identifier.isi | WOS:000708911300001 | - |
dc.publisher.place | Switzerland | - |